Background & Aims: Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III trial. Further evaluation is necessary to investigate the safety and efficacy of Ate/Bev in real settings. Methods: This was a multicentre retrospective analysis. Between May 2020 and February 2021, 138 patients received Ate/Bev as first-line treatment for advanced HCC from 11 institutions. We excluded patients with Child-Pugh B or C and BCLC D stage, and the remaining 121 patients were included in this analysis. Results: According to RECIST 1.1, the objective response and disease control rates were 24.0% and 76.0%. The median follow-up duration was 5.9 months (95% confidence interval [CI], 5.4-6.4), the median progression-free survival (PFS) was 6.5 months (95% CI, 4.1-9.0), and median overall survival (OS) was not reached (95% CI, not available). The most frequent grade 3-4 adverse event was aspartate aminotransferase elevation (10.7%). In the multivariate analyses, AFP increase (P =.037), baseline neutrophil-to-lymphocyte ratio (NLR) ≥ 5 (P =.023), and best response to stable disease or progressive disease (P =.019) were significantly associated with worse PFS. Macrovascular invasion (P =.048) and baseline NLR ≥5 (P <.001) were significantly associated with worse OS. Conclusions: Ate/Bev showed real-life efficacy and safety in Korean patients with advanced HCC, in line with results from phase III trial. Considering unfavourable survival outcomes of Ate/Bev in patients with elevated NLR, careful assessment of treatment response needs to be performed in this group.
|Number of pages||8|
|Publication status||Published - 2022 Mar|
Bibliographical noteFunding Information:
JC received research grants from Bayer and honoraria from Eisai. CY received research grants from Bayer, ONO pharmaceuticals, AstraZeneca, and Ipsen; honoraria from Bayer, ONO pharmaceuticals, AstraZeneca, Roche, BMS, MSD, Eisai, Ipsen, and AstraZeneca. HJC has a consulting or advisory role at Roche, Bayer, Eisai, ONO, BMS, and MSD. HYL received honoraria from Bayer, BMS, Ipsen, and Eisai; fees for advisory board participation from Bayer, BMS, Ipsen, Eisai, MSD, and Roche. The other authors have no potential conflicts of interest related to this article or the research described therein.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
All Science Journal Classification (ASJC) codes